Phase 2 clinical trial to investigate the safety and how both PF-04937319 and sitigliptin work to control blood sugar, inadequately controlled on metformin, in people who have been diagnosed with Type 2 Diabetes within the past 5 years To evaluate the dose-response of PF-04937319, administered once daily over 12 weeks in adults with T2DM on stable doses of metformin, on glycemic control.

• Country None
• organs None
• Specialty None

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS The primary objective is to characterize the dose-response of CP-690-550 over the range of 1-15 mg BID on ACR-20 response criteria at 12 weeks.

• Country None
• organs None
• Specialty None

Phase 3 Study of Inotuzumab Ozogamicin versus Investigator's Choice of Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia To compare the hematological remission, defined as CR (both CR and CRi), as reported by the external independent endpoint adjudication committee, in patients with relapsed/refractory ALL randomized to...

• Country None
• organs None
• Specialty None

A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer The primary objective of this study is to compare the confirmed objective response rate (ORR) by Week 19 following treatment with bevacizumab-Pfizer in combination with paclitaxel and carboplatin to b...

• Country None
• organs None
• Specialty None

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg dose) as compared to placebo in the treatment of subjects with PAH for 12 weeks, as determined by change from the...

• Country None
• organs None
• Specialty None

A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS To assess the safety and tolerability of voriconazole for the treatment of invasive candidiasis, including candidemia, and esophageal candidiasis in pediatric subjects 2 to <18 years of age.

• Country None
• organs None
• Specialty None

A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED SUBJECTS The primary objective is to assess efficacy of UK-453,061 when used in combination with tenofovir DF/emtricitabine, as measured by percentage of subjects with HIV-1 RNA <48 copies/mL at 48 weeks.

• Country None
• organs None
• Specialty None

PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET STUDY) To evaluate the efficacy of different dosing paradigms of PF-04523655 versus ranibizumab (comparator) in subjects with neovascular AMD.

• Country None
• organs None
• Specialty None

A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 The primary objective of this study is to evaluate the long term safety, tolerability, and immunogenicity of PF-04236921.

• Country None
• organs None
• Specialty None

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS Determine if the addition of filibuvir to a standard of care (SOC) regimen of pegylated interferon alpha 2a (Pegasys) and ribavirin (Copegus) significantly increases the proportion of subjects who ach...

• Country None
• organs None
• Specialty None